Pathophysiology of Lung Cancer: How Malignancy Develops and Progresses

Understanding the Pathophysiology of Lung Cancer

The pathophysiology of lung cancer describes the biological mechanisms by which normal bronchial epithelial cells transform into invasive malignant tumors. This process involves cumulative genetic and epigenetic alterations that disrupt cell cycle control, apoptosis, and DNA repair. As these changes accumulate, cells gain the ability to proliferate unchecked, invade surrounding tissues, and disseminate to distant organs. The two principal histological categories — non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) — arise from distinct cell types and exhibit different molecular profiles, yet they share core oncogenic pathways that drive tumor initiation, progression, and escape from host defenses. Understanding these mechanisms is essential for interpreting symptoms, staging disease, and selecting targeted therapies.

From Normal Cells to Malignant Transformation

Lung carcinogenesis typically begins in the bronchial epithelium, where repeated exposure to carcinogens such as tobacco smoke, radon, asbestos, or air pollution induces DNA damage. When repair mechanisms fail, critical genes become mutated. Proto-oncogenes like KRAS, EGFR, and BRAF may acquire gain-of-function mutations, while tumor suppressor genes such as TP53 and RB1 lose their ability to restrain cell growth. The resulting accumulation of driver mutations shifts cells from a normal state through dysplasia and carcinoma in situ to invasive carcinoma. This multistep process can span years to decades, and the specific mutational landscape varies with histology, smoking history, and demographic factors. Field cancerization — the concept that entire airways are exposed to carcinogens — explains why lung cancers frequently arise at multiple independent sites in patients with diffuse airway damage.

Tumor Growth, Angiogenesis, and Local Invasion

Once a malignant clone establishes itself, it must secure a blood supply to sustain growth beyond a few millimeters. Tumor cells secrete pro-angiogenic factors, most notably vascular endothelial growth factor (VEGF), which stimulate the formation of new blood vessels. This angiogenesis provides oxygen and nutrients while creating routes for future metastasis. Simultaneously, cancer cells degrade the extracellular matrix through matrix metalloproteinases and other proteases, enabling local invasion into the pleura, chest wall, or mediastinal structures. The tumor microenvironment — composed of immune cells, fibroblasts, and signaling molecules — can either restrain or facilitate progression. In many cases, tumors evade immune surveillance by expressing checkpoint ligands such as PD-L1, suppressing T-cell activity and promoting an immunosuppressive milieu.

Metastasis and Distant Spread

Metastasis remains the leading cause of mortality in lung cancer. Cells detach from the primary tumor, enter blood or lymphatic vessels, and survive in circulation as circulating tumor cells. They arrest in capillary beds of distant organs, extravasate, and establish micrometastases. Common sites include the brain, bones, liver, and contralateral lungs. The pathophysiology of metastasis involves epithelial-to-mesenchymal transition, altered cell adhesion, and adaptation to foreign microenvironments. Molecular determinants such as lymph node involvement and the presence of specific gene fusions or mutations influence the pattern and speed of dissemination, which in turn shapes prognosis and treatment strategy.

Paraneoplastic Syndromes and Systemic Effects

Lung cancers can produce systemic effects remote from the primary tumor through the secretion of hormones, cytokines, or antigenic proteins. Small cell lung cancer frequently causes ectopic adrenocorticotropic hormone (ACTH) secretion or the syndrome of inappropriate antidiuretic hormone (SIADH), leading to Cushing syndrome or hyponatremia. Squamous cell carcinomas may secrete parathyroid hormone-related peptide (PTHrP), resulting in hypercalcemia. Other paraneoplastic phenomena include Lambert-Eaton myasthenic syndrome, hypertrophic osteoarthropathy, and neurological syndromes mediated by autoantibodies. These manifestations arise because malignant cells retain or aberrantly activate secretory pathways normally restricted to their tissue of origin, and they often signal advanced or aggressive disease.

Molecular Pathways and Therapeutic Implications

Understanding the molecular pathophysiology of lung cancer has transformed treatment. Activating mutations in EGFR and ALK rearrangements define subsets of NSCLC that respond to tyrosine kinase inhibitors, while tumors with high PD-L1 expression or high tumor mutational burden may benefit from immune checkpoint inhibitors. In SCLC, loss of TP53 and RB1 is nearly universal, and the rapid proliferation and early metastasis of this subtype limit the effectiveness of surgery but create sensitivity to platinum-based chemotherapy and radiation. Biomarker testing — including next-generation sequencing, immunohistochemistry for PD-L1, and liquid biopsy for circulating tumor DNA — allows clinicians to tailor therapy to the specific biological drivers of an individual's tumor.

How Pathophysiology Shapes Clinical Presentation

The anatomical location and growth pattern of a lung tumor determine its clinical manifestations. Central tumors arising in the bronchi may cause cough, hemoptysis, or obstructive pneumonitis, while peripheral lesions may remain asymptomatic until they invade the pleura or chest wall. Pancoast tumors at the lung apex can invade the brachial plexus and sympathetic chain, producing shoulder pain and Horner syndrome. Pleural involvement leads to malignant effusions and dyspnea. Recognizing these patterns allows clinicians to link symptoms to tumor biology and stage, guiding diagnostic workup and timely intervention.